28 results about "Allogeneic graft" patented technology

Disclosed herein are methods for sequencing, comprising, providing a sample, wherein said sample comprises a plurality of nucleic acid (NA) molecules, isolating said plurality of NA molecules from said sample, amplifying said plurality of NA molecules, subjecting said plurality of NA molecules to one or more amplification reactions to generate a plurality of cDNA molecules, and sequencing said plurality of cDNA molecules or derivatives thereof. Also disclosed herein are systems, comprising, a processor, and a non-transitory computer readable storage medium encoded with a computer program that causes said processor to providing a sample, wherein said sample comprises a plurality of NA molecules, isolating said plurality of NA molecules from said sample, amplifying said plurality of NA molecules, subjecting said plurality of nucleic acid molecules to one or more amplification reactions to generate a plurality of cDNA molecules, and sequencing said plurality of cDNA molecules or derivatives thereof.

Embodiments of systems and methods for fixing soft tissue are disclosed herein. In some embodiments, soft tissue may be fixed to an attachment surface (such as bone, other soft tissue, other implants, or allograft or xenograft materials) by providing a helical suture in the soft tissue, wherein the soft tissue has a longitudinal axis along which the soft tissue undergoes tension under normal physiological conditions, and wherein a longitudinal axis of the helical suture in the soft tissue is oriented parallel to the longitudinal axis of the soft tissue; and securing the helical suture to an anchor secured to the attachment surface.

Improved allografts having controlled and consistent properties and useful for soft tissue repair, including breast reconstruction, and other surgical procedures, are disclosed. In one embodiment, an improved acellular dermal matrix (ADM) is produced from a skin sample, where the ADM consists essentially of a single dermal tissue type (e.g., papillary or reticular) and comprises a collagen matrix having substantially uniform density and porosity. In another embodiment, two ADMs are produced from the same dermal tissue type (e.g., papillary or reticular) of the same skin sample, each of which consists essentially of reticular dermis, and comprises a collagen matrix having substantially uniform density and porosity. All such improved ADMs are suitable for use in breast reconstruction and other tissue repair and modification surgery procedures.

A device and system for inserting and impacting bone dowel allografts or bone chips into a bone tunnel. The surgical impacting system includes a surgical tamp having a proximal end and a distal end with an elongated shaft extending therebetween. The surgical tamp has an inner channel extending therethrough from the proximal end to the distal end. The distal end of the surgical tamp can have a distal tip. The surgical tamp may have a handle at the proximal end or a proximal tip at the proximal end. The surgical tamp may also have one or more slots extending through the exterior surface of the elongated shaft and into the inner channel. The surgical tamp can be configured for insertion into a delivery tube. The delivery tube serves the purpose of containing a bone dowel or bone chips therein for smooth insertion into the joint.

Provided herein are a method of processing human birth tissue to create a variety of tissue forms that maintain high levels of beneficial compounds and increase tissue availability. Also provided are products made from the processed tissue forms, and application of these products in soft tissue repair and the treatment of wounds.

Provided herein are a method of processing human birth tissue to create a variety of tissue forms that maintain high levels of beneficial compounds and increase tissue availability. Also provided are products made from the processed tissue forms, and application of these products in soft tissue repair and the treatment of wounds.

There is disclosed an acellular dermal matrix (ADM) graft stored as a packaged ADM graft pocket product prepared by a process that includes providing a portion of ADM tissue having a thickness between 1 mm and 2 mm. The process includes scoring the portion of the ADM tissue into a pre-defined shape to form the domed shape ADM graft. The process includes verifying the thickness of the domed shape ADM graft; shaping the domed shape ADM graft to form an ADM graft pocket configured to receive a breast implant. The process includes packaging the ADM graft pocket to form a packaged ADM graft pocket. The process includes irradiating the packaged ADM graft pocket to a sterility assurance level of a desired level to form the packaged ADM graft pocket product. Other embodiments are also disclosed.

Provided herein are formulations for treating bone graft materials prior to implantation. Treating the bone graft materials with the formulations disclosed herein can restore the physiological and biochemical characteristics of bone. The bone graft can be a bone allograft. Also provided herein are methods for preparing the formulations and methods for preparing a bone graft for transplantation.

The invention features compositions and methods for treating transplant recipients (e.g., chronic allograft rejection) using a senolytic agent and an angiotensin II receptor antagonist or using a senolytic agent and senomorphic agent. The methods and compositions are useful in a variety of transplant settings including, without limitation, solid organ transplants including kidney, lung, heart, liver, intestine, or pancreas transplantation procedures and cellular transplants including but not limited to bone marrow transplants.

Disclosed herein are methods of treating a disease selected from the group consisting of graft versus host disease (GVHD), systemic sclerosis (scleroderma), chronic lung allograft dysfunction (CLAD), restrictive allograft syndrome (RAS), and obliterated bronchitis syndrome (BOS), using a combination of a BTK inhibitor, such as rezobrutinib, and besudil.

Chronic Lung Allograft Dysfunction (CLAD) is characterized by a progressive and irreversible decline in lung function affecting half of lung transplant recipients within five years and is the major cause of death contributing to a low median post-transplant survival. Disclosed herein is an optimized airway inflammation gene set (AI2) and AI2 score, as well as RSI, RS2, and RS3 subscores, for use in methods of treating or preventing CLAD, methods of treating or preventing graft failure, methods of treating or preventing transplant rejection, methods of treating or preventing small airway fibrosis, methods of treating or preventing antibody mediated rejection (AMR) and methods of reducing mortality associated with graft failure. Also disclosed are methods of detecting or diagnosing CLAD and methods of predicting transplant rejection.

Chronic Lung Allograft Dysfunction (CLAD) is characterized by a progressive and irreversible decline in lung function affecting half of lung transplant recipients within five years and is the major cause of death contributing to a low median post-transplant survival. Disclosed herein is an optimized airway inflammation gene set (AI2) and AI2 score, as well as RS1, RS2, and RS3 subscores, for use in methods of treating or preventing CLAD, methods of treating or preventing graft failure, methods of treating or preventing transplant rejection, methods of treating or preventing small airway fibrosis, methods of treating or preventing antibody mediated rejection (AMR) and methods of reducing mortality associated with graft failure. Also disclosed are methods of method of detecting or diagnosing CLAD and methods of predicting transplant rejection.

The present disclosure pertains to a method for treating Type 1 diabetes mellitus by using tolerogenic dendritic cells (tDCs) as an adjunct to stem cell-derived β-cell (SCislet) replacement therapy. The tDCs are genetically modified to induce immunotolerance and are administered in conjunction with SCislet autografts or allografts to enhance their survival and function, providing a potential cure or disease-modifying treatment for T1DM.

Provided herein are bioresorbable, bioregenerative composite materials and compositions to regenerate tissues or organs to repair tissue or organ defects and constructs printed from the same as 3D structures shaped and sized to fill a tissue or organ defect. The composite materials are bioresorbable polymers, for example, polycaprolactone, and a bioresorbable graft material, for example, demineralized bone matrix. Also provided are methods for making the composite materials and compositions and methods for regenerating tissues or organs and repairing a tissue or organ defect using the constructs.

Disclosed herein includes a method for treating antibody-mediated kidney allograft rejection, comprising treating a subject determined to suffer from antibody-mediated kidney allograft rejection more than 6 months after transplantation by administering an anti-CD38 antibody or antigen-binding fragment thereof (e.g., daratumumab, felzartamab, or isatuximab) to the subject; extracting cell-free DNA from a blood, plasma, serum or urine sample collected from the subject after conclusion of the treatment; quantifying an amount of donor-derived cell-free DNA, a percentage of donor-derived cell-free DNA out of total cell-free DNA, or both, in the extracted DNA; and retreating the subject with an anti-CD38 antibody or antigen-binding fragment thereof if the amount of donor-derived cell-free DNA, the percentage of donor-derived cell-free DNA out of total cell-free DNA, or both, exceed one or more threshold values.

Improved allografts having controlled and consistent properties and useful for soft tissue repair, including breast reconstruction, and other surgical procedures, are disclosed. In one embodiment, an improved acellular dermal matrix (ADM) is produced from a skin sample, where the ADM consists essentially of a single dermal tissue type (e.g., papillary or reticular) and comprises a collagen matrix having substantially uniform density and porosity. In another embodiment, two ADMs are produced from the same dermal tissue type (e.g., papillary or reticular) of the same skin sample, each of which consists essentially of reticular dermis, and comprises a collagen matrix having substantially uniform density and porosity. All such improved ADMs are suitable for use in breast reconstruction and other tissue repair and modification surgery procedures.

The invention relates to biomarker signatures for stratifying the graft function and / or infection status of a solid organ transplant recipient, methods of using the same and kits for the detection thereof. In particular, the present invention relates to biomarker signatures for stratifying Chronic Lung Allograft Dysfunction (CLAD) and / or infection status of a lung transplant recipient.

The present invention relates to methods of treating or preventing ischemia reperfusion injury (IRI) in a subject receiving a donor organ transplant, wherein the methods involve administration of a complement factor 2 (C2) inhibitor to the subject. The present invention also relates to methods of improving allograft function and also to methods of reducing the risk of allograft loss in a subject receiving a donor organ transplant, wherein the methods involve administration of a C2 inhibitor to the subject. Furthermore, the present invention relates to methods of treating or preventing delayed graft function (DGF) in a subject receiving a kidney transplant, wherein the methods involve administration of a C2 inhibitor to the subject. The C2 inhibitor may be empasiprubart.

Rapid recovery with extended ultra-oxygenated preservation (REUP) can ethically and cost-effectively improve recovery and transplant outcomes for donation after circulatory death (DCD) allografts. REUP can include a portable system, method, and specialized ultra-oxygenated solution(s). The portable system includes a flush circuit and at least one cannula connected to the DCD allograft for flushing the ultra-oxygenated solution into the in-situ DCD allograft. The flush circuit can include at least one reservoir for the ultra-oxygenated solution, a temperature control device, a pressure regulation system, optionally an oxygenator, and tubing for connecting components. The system is noted as easily portable and cost effective for use in many conditions, including environments where traditional recovery systems cannot be used. The methods and solution can be specialized depending on donor demographic information, previous surgeries, and / or allograft type.

There is disclosed a packaged allograft implant configured for implantation in a human recipient. In an embodiment, the packaged allograft implant includes an acellular dermal matrix sheet having a top surface and a bottom surface in opposition to one another, a perimeter surrounding the top surface and the bottom surface, and a thickness extending between the top surface and the bottom surface. The packaged allograft implant further includes a mesh pattern extending across at least a portion of the top surface and the bottom surface of the acellular dermal matrix sheet, the mesh pattern providing through-holes extending between the top surface and the bottom surface of the acellular dermal matrix sheet, and the mesh pattern having a plurality of mesh lines extending in a first direction and a second direction. The first direction and the second direction are orthogonal to one another so as to allow a given amount of stretch in each of the first direction and the second direction. Other embodiments are also disclosed.

The present invention relates to compounds of formula 1 or 2,wherein R1 and R3 are purine or a purine analog and R2 and R4 are a small functional group. The invention also relates to intermediates of the synthesis of compounds of formula 1 or 2. Compounds of formula 1 or 2 are Janus kinase inhibitors and thus useful in the treatment of a disease, particularly an autoimmune disease, cancer, Alzheimer's disease or useful in preventing the rejection of an allograft or xenograft.

Bladder cancer primarily affects older adults, with radical surgery often leading to significant complications due to the use of bowel tissue for bladder reconstruction. Provided herein is a new approach using cryopreserved tissue from cadaveric vessels that avoids these complications. This new method makes surgery safer and recovery quicker, reducing hospital stays and improving patients' quality-of-life. This disclosed method is a major advancement in treating muscle-invasive bladder cancer, offering minimal side effects and a faster return to normal life.

The present application relates to a bi-functional therapeutic for treating cancer that includes a targeting component which targets a tumor-associated antigen and an enzyme which, when delivered to a tumor by said targeting component, converts the tumor phenotype to that of an incompatible allograft or xenograft. The enzyme is coupled to the targeting component. Also disclosed is a method for treating cancer comprising administering the bi-functional therapeutic.

A method of predicting the development of chronic lung allograft dysfunction (CLAD) in lung transplant patients using N-myc-interactor (NMI) as a biomarker and associated treatment thereof is presented. Also presented is a method of reducing the risk of CLAD by administering a therapeutic agent capable of increasing NMI in the patient. NMI is a critical regulator of epithelial-to-mesenchymal transition (EMT) and an important precursor to development of CLAD. NMI expression is reduced in CLAD patients and can be used as an early diagnostic biomarker to predict the development of CLAD. NMI can also be used as a drug target for a therapeutic to increase expression of NMI and treat chronic lung disease such as CLAD. Therapeutics comprising NMI protein or NMI gene can be used as potential treatments for chronic lung diseases such as CLAD.

Disclosed herein includes a method for assessing a lung transplant, comprising extracting cfDNA from a blood sample of a lung transplant recipient; preparing a sequencing library from the extracted cell-free DNA and performing high-throughput sequencing on the sequencing library; quantifying an amount of donor-derived cell-free DNA and / or a percentage of donor-derived cell-free DNA; quantifying an amount of one or more inflammatory mediators in a blood sample or a bronchoalveolar lavage sample of the lung transplant recipient and / or a performance of the lung transplant recipient in one or more physiological tests; and performing a multi-modal assessment to determine the presence or absence of chronic lung allograft dysfunction (CLAD) in the lung transplant recipient.